The good, the fat, and the ugly: Targeting lipid overload to boost central nervous system repair

Multiple sclerosis (MS) is a devastating neurological disease and one of the most prevalent autoimmune disorders in the Western world. Foamy macrophages loaded with myelin-derived lipid droplets (LDs) are a pathological hallmark of MS lesions. 

Recent research showed that excessive accumulation of intracellular LDs induces a pro-inflammatory macrophage phenotype, which promotes neuroinflammation and impairs central nervous system (CNS) repair. To date, however, the molecular pathways responsible for excessive accumulation of LDs in lesion-associated macrophages remain to be uncovered.

Our findings indicate that perturbed activity of multiple metabolic pathways underpins excessive intracellular LD accumulation in foamy macrophages, thereby driving the induction of a disease-promoting macrophage phenotype in MS lesions. First, we find that sustained intracellular accumulation of myelin is associated with impaired lipophagy, a selective form of autophagy involved in LD turnover. Second, we demonstrate that increased abundance of the LD protein perilipin-2 (PLIN2) impairs lipolysis-mediated degradation of LDs. Finally, our results indicate that excessive myelin uptake by macrophages hampers cholesterol efflux by promoting the ubiquitination and degradation of the cholesterol efflux transporter ABCA1 via the ubiquitin E3 ligase A (UBE3A). Importantly, pharmacological activation of lipophagy and genetic loss of PLIN2 and UBE3A reduced cellular LD load in foamy macrophages, induced an anti-inflammatory phenotype of these cells, and enhanced CNS repair in ex vivo and in vivo toxin-induced demyelination models. In aggregate, obtained results provide increased insight into MS lesion pathology, and identify multiple novel pathways as promising therapeutic targets to boost CNS repair in MS and other neurological diseases characterized by the presence of foamy macrophages.


Melanie Loix (1,2), Mansour Haidar (1,2), Elien Wouters (1,2), Mattijs Punt (3,4), Sam Vanherle (1,2), Tess Dierckx (1,2), Rob Verhagen (3,4), Suzanne van Wouw (5), Jonas Dehairs (6), Johannes V. Swinnen (6), Ben Distel (3,4), Ype Elgersma (3,4), Noam Zelcer (5), Jerome J.A. Hendriks (1,2), Jeroen F.J. Bogie (1,2)


(1) Biomedical Research Institute, School of Life Sciences, Hasselt University, Diepenbeek, Belgium. (2) University MS Center Hasselt, Pelt, Belgium. (3) Department of Neuroscience, Erasmus University Medical Center, Rotterdam, The Netherlands. (4) ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus University Medical Center, Rotterdam, The Netherlands. (5) Department of Medical Biochemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands. (6) Department of Oncology, Laboratory of Lipid Metabolism and Cancer, LKI - Leuven Cancer Institute, KU Leuven.

Presenting author

Melanie Loix, PhD Student, Hasselt University
Contact us now
Registrations are now open!

KNOWLEDGE FOR GROWTH Institutional Partners

KNOWLEDGE FOR GROWTH Supporting Partners

FLANDERS.BIO Strategic Partners